Rising burden of chronic conditions and increasing surgical volume, leading to higher demand for blood and its components, drives the apheresis equipment market growth

Industry : Healthcare    

Augmenting rise in incidence of diseases such as myasthenia gravis, multiple sclerosis, malaria, dengue, leukemia, and sickle cell anemia is expected to positively impact the apheresis equipment market.

Rising prevalence of these diseases over the forecast period drives the apheresis equipment market. The following table represents the current prevalence of these diseases within the U.S. region, which forms the highest contributing region as of 2015:

Diseases

Prevalence (per 100,000 population)

Reporting Body

Myasthenia Gravis

14-20

Myasthenia Gravis Foundation of America

Multiple Sclerosis

90-100

National Multiple Sclerosis Society

Pulmonary vascular diseases

10-52

American Thoracic Society

Hypercholesterolemia

31000-37000

The Familial Hypercholesterolemia Foundation

Sickle cell disease

31-35

Center for Disease Control and Prevention

Leukemia

47-53

Leukemia and Lymphoma Society

Dengue

2000-2300

National Institutes of Health

 

Coupled with the rise in demand, technological up gradation/automation of existing product line and development of new products further boost growth. In an attempt to lower the depletion of RBC in products obtained through apheresis, Cesca installed their platform AutoXpress.

During the annual American Association of Blood Banks conference in 2015, the company highlighted the advantages of AutoXpress and also introduced their latest project CellWerks. By application of this platform in pipeline apheresis machines, one may witness faster and better utility in curing hematology and oncology diseases.

Certain strategic initiatives undertaken by industry participants in the recent years, towards the development of the market are:

  • In October 2016, Fresenius Kabi (Fenwal) received FDA clearance for the product Aurora. The system is expected to separate plasma components from whole blood using plasmapheresis.

  • In July 2016, Terumo BCT received USD 1.9 million as award by the U.S. Government to propel the development of blood components, such as freeze-dried plasma.

  • In March 2015, Lixelle apheresis columns manufactured by Kaneka Corporation, gained approval by the U.S. FDA to be used in kidney failure.

  • In January 2015, the U.S. FDA approved the use of Liposorber systemfor the purpose of blood processing.

  • In March 2014, Therakos signed an exclusive distribution agreement with Terumo BCT, wherein Terumo would be the sole supplier of UVAR XTS and THERAKOS CELLEX in the Latin American region.

  • In January 2014, Haemonetics entered into an agreement with HemeXcel to supply whole blood collection products.

  • In April 2013, B. Braun opened its expanded production site in Gyongyos, Hungary. This production site has a capacity to manufacture 100 million products per year.

  In-depth report on global apheresis equipment market by Grand View Research:

http://www.grandviewresearch.com/industry-analysis/apheresis-equipment-market

To schedule a free market intelligence database demo, please complete the form below:

This website is secure and your personal details are safe. Privacy policy